Son-Of-Xigris Goes to Biotech--Where it Belongs?
Executive Summary
When Eli Lilly licensed the follow-on drug candidate to sepsis treatment Xigris to Cardiome, it was a tacit acknowledgment that this family of specialist products may be better suited to biotech. Perhaps they should have done the same with Xigris.
You may also be interested in...
Sepsis: A Market in Need
In this era of health care reform, critical care medicine remains a strong market for innovative technologies that can improve patient outcomes, shorten ICU stays, and ultimately reduce the overall cost of care. Within this space, one segment that is ripe for innovation is the market for severe sepsis products.Although the last 20 years have seen advances in treatment and a marked increase in the understanding of sepsis and septic shock, severe sepsis remains one of the most significant challenges in critical care today.
Deals Of The Week: GSK/Apeiron, Cephalon/Mepha, Medco/DNA Direct...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
GSK Hunts for Novelty By Paying £11m To Apeiron In A Respiratory Deal
The privately owned Austrian biotech attracts GSK to a Phase I ARDS biologic.